Replimune Group (REPL) Fundamentals 2026 — Revenue Analysis | SniperIQ
Replimune Group (REPL) is a US-listed Healthcare company in Biotechnology with a market capitalization of $924M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Replimune Group's market cap?
Replimune Group (REPL) has a market capitalization of approximately $924M, trading at
What is Replimune Group's P/E ratio?
Replimune Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Replimune Group?
Replimune Group runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Replimune Group pay a dividend?
Replimune Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Replimune Group financially healthy?
Replimune Group carries a debt-to-equity ratio of 0.67x and a current ratio of 4.79x, with a market beta of 0.87. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Replimune Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Replimune Group (REPL) the key facts are: market cap $924M, 52-week range 1.5-12.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Replimune Group's full fundamentals live
Get Replimune Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.